[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial

(2015) A. Davidson et al.   ANNALS OF ONCOLOGY

A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)

(2015) A.-M. C. Dingemans et al.   ANNALS OF ONCOLOGY

Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion

(2015) Wouter van Elmpt et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Comparative Study of the Hypoxia PET Tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a Preclinical Tumor Model

(2015) Sarah G.J.A. Peeters et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PET in the management of locally advanced and metastatic NSCLC

(2015) Willem Grootjans et al.   Nature Reviews Clinical Oncology

New ways to image and target tumour hypoxia and its molecular responses

(2015) Ludwig J. Dubois et al.   RADIOTHERAPY AND ONCOLOGY

Does Early PET/CT Assesment of Response to Chemotherapy Predicts Survival in Patients With Advanced Stage Non-Small-Cell Lung Cancer?

(2015) Cetin Ordu et al.   MEDICINE

In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging

(2014) C. M. L. Zegers et al.   CLINICAL CANCER RESEARCH

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

(2014) Ronald Boellaard et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

[18F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients

(2014) Mammar Hachemi et al.   PLoS One

Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation

(2014) Chintan Parmar et al.   PLoS One

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab

(2013) K. Skougaard et al.   JOURNAL OF NUCLEAR MEDICINE

Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [11C]docetaxel

(2013) Astrid A. M. van der Veldt et al.   Frontiers in Oncology

Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non-Small Cell Lung Cancer

(2012) W. van Elmpt et al.   JOURNAL OF NUCLEAR MEDICINE

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET

(2011) D. Kahraman et al.   JOURNAL OF NUCLEAR MEDICINE

Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer

(2011) Manushka Vaidya et al.   RADIOTHERAPY AND ONCOLOGY

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging

(2010) A.-M. C. Dingemans et al.   ANNALS OF ONCOLOGY

Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy

(2009) I.M.E. Desar et al.   CANCER TREATMENT REVIEWS

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials

(2008) Ronald Boellaard et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING